Primary Graft Failure, but Not Relapse, May Be Identified by Early Chimerism Following Double Cord Blood Unit Transplantation

Overview

Journal Blood Adv

Specialty Hematology

Date 2021 Oct 26

PMID 34700343

Authors

Rachael Hough

Andre Lopes

Pip Patrick

Nigel Russell

Kavita Raj

Eleni Tholouli

John A Snowden

Matthew Collin

Nadjet El-Mehidi

Anthony Lawrie

Laura Clifton-Hadley

Paul Veys

Charles Craddock

Stephen Mackinnon

Gordon Cook

Bronwen Shaw

David Marks

Affiliations

Soon will be listed here.

Abstract

Umbilical cord blood transplantation (UCBT) has increased access to potentially curative therapy for patients with life-threatening disorders of the bone marrow and immune system. The introduction of reduced intensity conditioning (RIC) regimens and double umbilical cord unit infusions (DUCBT) has broadened the applicability of UCBT to more frail or larger recipients. The kinetics of chimerism after RIC DUCBT and their clinical utility are poorly understood. The RIC CBT trial reported here sought to prospectively evaluate the role of lineage-specific chimerism after DUCBT in adult patients with hematologic malignancies in the United Kingdom. Fifty-eight patients with a median age of 52 years were recruited, with overall and progression-free survivals of 59% (95% confidence interval [CI], 45%-71%) and 52% (95% CI, 39%-64%), respectively, at 2 years. Nonrelapse mortality was 4% (95% CI, 1%-13%) at day 100, and the relapse rate was 31% (95% CI, 21%-45%) at 1 year. Peripheral blood lineage-specific chimerism was feasible from day 7 after transplant onward. Five patterns of chimerism were observed including (1) complete single unit dominance (39 patients), (2) sustained donor-donor mixed chimerism (3 patients), (3) sustained donor-recipient mixed chimerism (5 patients), (4) dominance reversion (1 patient), and (5) primary graft failure (4 patients). The RIC CBT trial enabled adult patients with high-risk hematologic malignancies to safely access UCBT in the United Kingdom and provided novel insights into the kinetics of donor and recipient chimerism after RIC DUCBT that are clinically relevant. This trial was registered at https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003845-41/GB as #NCT00959231 and EudraCT 2004-003845-41.

References

Ballen K, Spitzer T, Yeap B, McAfee S, Dey B, Attar E . Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007; 13(1):82-9. PMC: 2947324. DOI: 10.1016/j.bbmt.2006.08.041. View

Dubovsky J, Daxberger H, Fritsch G, Printz D, Peters C, Matthes S . Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. Leukemia. 1999; 13(12):2059, 2060-9. View

Moscardo F, Sanz J, Senent L, Cantero S, Rubia J, Montesinos P . Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies. Haematologica. 2009; 94(6):827-32. PMC: 2688574. DOI: 10.3324/haematol.2008.000935. View

Elkaim E, Picard C, Galambrun C, Barlogis V, Loundou A, Curtillet C . Peripheral blood cells chimerism after unrelated cord blood transplantation in children: kinetics, predictive factors and impact on post-transplant outcome. Br J Haematol. 2014; 166(4):557-65. DOI: 10.1111/bjh.12918. View

Laughlin M, Eapen M, Rubinstein P, Wagner J, Zhang M, Champlin R . Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004; 351(22):2265-75. DOI: 10.1056/NEJMoa041276. View

Introna M, Pievani A, Borleri G, Capelli C, Algarotti A, Mico C . Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol Blood Marrow Transplant. 2010; 16(11):1603-7. DOI: 10.1016/j.bbmt.2010.05.015. View

Verneris M, Wagner J . UCB and atmospheric noise. Blood. 2010; 115(4):754-5. DOI: 10.1182/blood-2009-11-251819. View

Avery S, Voss M, Gonzales A, Lubin M, Castro-Malaspina H, Giralt S . Importance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantation. Bone Marrow Transplant. 2011; 47(8):1056-60. PMC: 3970438. DOI: 10.1038/bmt.2011.236. View

Wagner J, Barker J, DeFor T, Baker K, Blazar B, Eide C . Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002; 100(5):1611-8. DOI: 10.1182/blood-2002-01-0294. View

10.

Somers J, Brand A, van Hensbergen Y, Mulder A, Oudshoorn M, Sintnicolaas K . Double umbilical cord blood transplantation: a study of early engraftment kinetics in leukocyte subsets using HLA-specific monoclonal antibodies. Biol Blood Marrow Transplant. 2012; 19(2):266-73. DOI: 10.1016/j.bbmt.2012.09.022. View

11.

Gutman J, Turtle C, Manley T, Heimfeld S, Bernstein I, Riddell S . Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood. 2009; 115(4):757-65. PMC: 2815516. DOI: 10.1182/blood-2009-07-228999. View

12.

Tomizawa D, Aoki Y, Nagasawa M, Morio T, Kajiwara M, Sekine T . Novel adopted immunotherapy for mixed chimerism after unrelated cord blood transplantation in Omenn syndrome. Eur J Haematol. 2005; 75(5):441-4. DOI: 10.1111/j.1600-0609.2005.00535.x. View

13.

Song K, Sun Z, Liu H, Geng L, Ding K, Wang X . Primary research on unrelated double umbilical cord blood transplantation and implantation kinetics. Hematology. 2013; 18(5):253-9. DOI: 10.1179/1607845413Y.0000000074. View

14.

Tanoue S, Konuma T, Takahashi S, Watanabe E, Sato N, Watanabe N . Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome. Leuk Lymphoma. 2017; 58(12):2973-2975. DOI: 10.1080/10428194.2017.1318440. View

15.

Hashem H, Lazarus H . Double umbilical cord blood transplantation: relevance of persistent mixed-unit chimerism. Biol Blood Marrow Transplant. 2014; 21(4):612-9. DOI: 10.1016/j.bbmt.2014.09.003. View

16.

Eldjerou L, Chaudhury S, Baisre-de Leon A, He M, Arcila M, Heller G . An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment. Blood. 2010; 116(19):3999-4006. PMC: 2981548. DOI: 10.1182/blood-2010-03-276212. View

17.

Brunstein C, Barker J, Weisdorf D, DeFor T, Miller J, Blazar B . Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007; 110(8):3064-70. PMC: 2018678. DOI: 10.1182/blood-2007-04-067215. View

18.

Avery S, Shi W, Lubin M, Gonzales A, Heller G, Castro-Malaspina H . Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood. 2010; 117(12):3277-85. PMC: 3069669. DOI: 10.1182/blood-2010-08-300491. View

19.

Lamers C, Wijers R, van Bergen C, Somers J, Braakman E, Gratama J . CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation. Blood. 2016; 128(17):2165-2174. DOI: 10.1182/blood-2016-06-718619. View

20.

Brunstein C, Miller J, McKenna D, Hippen K, DeFor T, Sumstad D . Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood. 2015; 127(8):1044-51. PMC: 4768428. DOI: 10.1182/blood-2015-06-653667. View